These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 1535788)

  • 1. An objective and subjective assessment of uterine blood loss in postmenopausal women on hormone replacement therapy.
    Sporrong T; Rybo G; Mattsson LA; Vilbergson G; Crona N
    Br J Obstet Gynaecol; 1992 May; 99(5):399-401. PubMed ID: 1535788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrauterine 10 microg and 20 microg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response.
    Raudaskoski T; Tapanainen J; Tomás E; Luotola H; Pekonen F; Ronni-Sivula H; Timonen H; Riphagen F; Laatikainen T
    BJOG; 2002 Feb; 109(2):136-44. PubMed ID: 11888095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.
    Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ
    Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pilot study to evaluate a new regimen to treat climacteric complaints with cyclic combined oestradiol valerate/medroxyprogesterone acetate.
    Hellberg D; Nilsson S
    Maturitas; 1987 Apr; 9(1):103-7. PubMed ID: 2955203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative study of two levonorgestrel-containing hormone replacement therapy regimens of efficacy and tolerability variables.
    Gräser T; Rössner P; Schubert K; Müller A; Bönisch U; Oettel M
    Maturitas; 1997 Dec; 28(2):169-79. PubMed ID: 9522325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transdermal oestradiol gel in the treatment of the climacterium: a comparison with oral therapy.
    Hirvonen E; Lamberg-Allardt C; Lankinen KS; Geurts P; Wilén-Rosenqvist G
    Br J Obstet Gynaecol; 1997 Nov; 104 Suppl 16():19-25. PubMed ID: 9389779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response.
    Kalogirou D; Antoniou G; Karakitsos P; Kalogirou O; Antoniou D; Giannikos L
    Int J Fertil Menopausal Stud; 1996; 41(6):522-7. PubMed ID: 9010746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential estrogen and progestogen therapy: assessment of progestational effects on the postmenopausal endometrium.
    Byrjalsen I; Thormann L; Meinecke B; Riis BJ; Christiansen C
    Obstet Gynecol; 1992 Apr; 79(4):523-8. PubMed ID: 1532445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of combined hormone replacement therapy on serum lipid metabolism: new aspects.
    Alexandersen P; Haarbo J; Christiansen C
    Gynecol Endocrinol; 1997 Aug; 11(4):281-8. PubMed ID: 9272426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrauterine release of levonorgestrel--a new way of adding progestogen in hormone replacement therapy.
    Andersson K; Mattsson LA; Rybo G; Stadberg E
    Obstet Gynecol; 1992 Jun; 79(6):963-7. PubMed ID: 1579323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bleeding patterns in postmenopausal women using continuous combination hormone replacement therapy with conjugated estrogen and medroxyprogesterone acetate or with 17beta-estradiol and norethindrone acetate.
    Odmark IS; Jonsson B; Bäckström T
    Am J Obstet Gynecol; 2001 May; 184(6):1131-8. PubMed ID: 11349178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progestogens: therapeutic and adverse effects in early post-menopausal women.
    Marslew U; Riis B; Christiansen C
    Maturitas; 1991 Mar; 13(1):7-16. PubMed ID: 1830636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical evaluation of the therapeutic effectiveness of ethinyl oestradiol and oestrone sulphate on prolonged bleeding in women using depot medroxyprogesterone acetate for contraception. World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Long-acting Systemic Agents for Fertility Regulation.
    Said S; Sadek W; Rocca M; Koetsawang S; Kirwat O; Piya-Anant M; Dusitsin N; Sethavanich S; Affandi B; Hadisaputra W; Kazi A; Ramos RM; d'Arcangues C; Belsey EM; Noonan E; Olayinka I; Pinol A
    Hum Reprod; 1996 Oct; 11 Suppl 2():1-13. PubMed ID: 8982739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, placebo-controlled, cross-over trial to assess the side effects of medroxyprogesterone acetate in hormone replacement therapy.
    Kirkham C; Hahn PM; Van Vugt DA; Carmichael JA; Reid RL
    Obstet Gynecol; 1991 Jul; 78(1):93-7. PubMed ID: 1828550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicentre randomised trial to compare uterine safety of raloxifene with a continuous combined hormone replacement therapy containing oestradiol and norethisterone acetate.
    Neven P; Lunde T; Benedetti-Panici P; Tiitinen A; Marinescu B; de Villiers T; Hillard T; Cano A; Peer E; Quail D; Nickelsen T;
    BJOG; 2003 Feb; 110(2):157-67. PubMed ID: 12618160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy.
    Varila E; Wahlström T; Rauramo I
    Fertil Steril; 2001 Nov; 76(5):969-73. PubMed ID: 11704119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of continuous combined hormone replacement therapy in early postmenopausal women.
    Mattsson LA; Skouby S; Rees M; Heikkinen J; Kudela M; Stadnicki-Kolendo A; Mattila L; Salminen K; Vuorela A; Mustonen M;
    Menopause Int; 2007 Sep; 13(3):124-31. PubMed ID: 17785038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two new combinations of estrogen and progestogen for prevention of postmenopausal bone loss: long-term effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding.
    Marslew U; Overgaard K; Riis BJ; Christiansen C
    Obstet Gynecol; 1992 Feb; 79(2):202-10. PubMed ID: 1309944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Menopause Study Group.
    Archer DF; Pickar JH; Bottiglioni F
    Obstet Gynecol; 1994 May; 83(5 Pt 1):686-92. PubMed ID: 8164926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy.
    Simon JA; Liu JH; Speroff L; Shumel BS; Symons JP
    Am J Obstet Gynecol; 2003 Jan; 188(1):92-9. PubMed ID: 12548201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.